

- Gemifloxacin
 action of, 931t, 932–933
 for community-acquired pneumonia, 767t, 808t
 for gonococcal infections, 1008
 indications for, 943
 resistance to, 931t
- Gemigliptin, 2414t
- Gemtuzumab, 683, 1795, 1796, 1798
- Gender bias, 16e-4
- Gender differences, 6e-1
- Gene(s). *See also specific genes*
 assortment and segregation during meiosis, 427–428, 430f
 definition of, 427
 mutations. *See* Mutation(s)
 regulatory regions of, 427, 428f
 structure of, 427
- Gene conversion, 434
- Gene expression
 alterations of, 91e-2t, 94e-3, 102e-7–8, 102e-8f
 in cancer cells, 101e-7
 epigenetic regulation of, 429–431, 431f
 regulation by transcription factors, 428–429, 428f, 431t
- Gene Expression Omnibus, 101e-7
- Gene network, 87e-3, 87e-6f, 87e-7f
- Generalized anxiety disorder, 2709, 2712t
- Generalized epilepsy with febrile seizures, 2545t
- Generalized seizures. *See* Seizure(s), generalized
- Gene silencing, 101e-4
- Gene therapy, 91e-1
 for adenosine deaminase deficiency, 91e-2
 for adrenoleukodystrophy, 91e-2–3
 for cancer, 91e-2f, 91e-3t, 91e-4
 for cardiovascular disease, 91e-2f, 91e-4
 complications of, 91e-2, 91e-2t
 delivery vehicles for, 91e-1t
 for genetic disorders, 91e-1–3
 for heart failure, 1515
 for hemophilia, 91e-3
 for immunodeficiency disorders, 91e-1–2, 423, 2108
 for Leber's congenital amaurosis, 91e-3
 for leukemia, 91e-4
 for LPL deficiency, 2440
 for macular degeneration, 91e-3
 for PD, 2617
 for sickle cell anemia, 635, 639
 strategies for, 91e-1
 taking history from subjects in clinical trials, 91e-5, 91e-5t
 for thalassemia, 639
 for therapeutic angiogenesis, 91e-4
 for vascular disease, 91e-4
 viral vectors for, 91e-1t, 214e-9, 225e-2
- Genetic counseling, 449
 directive, 449
 ethical issues in, 445
 in familial cancer syndromes, 101e-6–7, 101e-8f
 indications for, 449, 449t
 in mitochondrial DNA diseases, 85e-9
 nondirective, 449
 pretest, 449–450
- Genetic disorders. *See also specific disorders*
 adult-onset
 family history in, 446–447, 447f
 genetic testing for, 447–449, 448f. *See also* Genetic testing
 inheritance patterns in, 446
 therapeutic interventions for, 450–451, 450t
 animal models of, 431–432
 approach to the patient, 442, 444f
 chromosome disorders. *See* Chromosome abnormalities/disorders
 complex, 440–441
 databases/websites, 426t
 diagnosis of, 425
 family history in, 442–443
 identifying disease-causing gene in, 442t, 443
- Mendelian. *See* Mendelian disorders
 mitochondrial DNA. *See* Mitochondrial DNA diseases
 multifactorial, 425, 440–441, 441t, 446
 mutational analysis in, 444–445
 penetrance of, 446
 polygenic, 426+, 441t
 prenatal diagnosis, 444
 transmission of. *See* Mutation(s)
 variable expression of, 446
 X-linked. *See* X-linked disorders
 Y-linked, 439
- Genetic education, 449–450
- Genetic Information Nondiscrimination Act (GINA), 101e-6, 445, 449, 480e-6
- Genetic linkage, 441–442, 442t
- Genetic privacy, 445
- Genetics, 425
 applications in clinical medicine, 446
 databases/websites, 426t
 impact on medical practice, 425
 population, 442
- Genetic testing
 approach to, 448–449, 448f
 ethical issues in, 445
 for familial cancer syndromes, 101e-6–7, 101e-8f
 family relationships and, 448–449
 follow-up care after, 449
 informed consent in, 443, 449, 480e-5
 limitations to, 480e-5–6
 methods for, 444–445, 447–449
 predisposition testing, 448
 presymptomatic, 448
 screening programs, 443–444
- Gene transfer, horizontal, 769t
- Genistein, 580
- Genital tract, anaerobic flora of, 1094, 1095t
- Genital tract infections
 abscesses, 849
 anaerobic bacterial, 1099
 HSV. *See* Herpes simplex virus (HSV) infections, genital
 tuberculosis, 1110
 warts, 351, 829, 1198, 1199f, 1200–1201. *See also* Condyloma acuminata (anogenital warts)
- Genital ulcer(s)
 chancroid. *See* Chancroid
 clinical features of, 880t
 diagnosis of, 879–880
 donovanosis. *See* Donovanosis
 etiology of, 870t, 879
 HIV transmission and, 1221, 1221f
 HSV. *See* Herpes simplex virus (HSV) infections, genital
 lymphogranuloma venereum. *See* Lymphogranuloma venereum
 treatment of, 879t, 880
- Genome, 425, 769t. *See also* Human genome
- Genome-wide association studies (GWAS)
 advantages and limitations of, 442t
 of complex traits, 425, 442, 442f
 in neurologic diseases, 444e-1
 in pharmacogenomics, 38–39
- Genomic imprinting. *See* Imprinting
- Genomic medicine, 443
- Genomics, 5–6, 425. *See also* Pharmacogenomics
 comparative, 2
 databases/websites, 426t
 functional, 426, 428
 global health and, 445
 impact on medical practice, 425
 in infectious disease. *See* Infectious diseases, genomics of
 stem cell, 455
 terminology of, 769t
- Genotoxicity, 91e-2t
- Genotype, 435
- Genotype-phenotype correlation
 in common disease types, 87e-4f
 definition of, 435
 in sickle cell anemia, 87e-3, 87e-5f
 in von Hippel–Lindau disease, 435
- Genotyping, 40, 41
- Gentamicin
 action of, 930, 931t
 adverse effects of, 821, 942
 for *Bartonella* endocarditis, 1081t
 for *Brucella* infections, 194e-4
 for burn-wound infection, 166e-3
 for *Campylobacter* infections, 1061
 for donovanosis, 198e-2
 for health care–associated pneumonia, 767t, 812t
 indications for, 940t
 for infective endocarditis, 821, 822t, 823, 823t, 824, 963
 intratympanic, for Ménière's disease, 219
 for *L. monocytogenes* infections, 983
 for meningitis, 887t, 889, 889t
 for necrotizing fasciitis, 780t
 for pelvic inflammatory disease, 878t, 879
 for plague, 261e-5, 261e-5t, 1074–1075, 1074t
 in pregnancy and lactation, 937t
 prophylactic, 945t
 resistance to, 821, 931t, 934, 940t, 976
 for septic shock, 780t
 for skin and soft tissue infections, 832
 therapeutic monitoring of, 2765t
 for trench fever, 1081t
 for tularemia, 261e-5t, 261e-7, 1069–1070
- Genu valgum, 2221, 2228, 2228f
- Genu varum, 2221, 2228, 2228f
- Geographic tongue, 46e-3f, 241t, 342f
- Gephyrin, 372e-25t
- Gerbil bite-wound, 167e-1
- GERD. *See* Gastroesophageal reflux disease (GERD)
- Geriatric syndromes, 73f, 76, 79. *See also* Aging; Elderly
- German measles. *See* Rubella (German measles)
- Germ cell(s)
 ovarian, 2349, 2375–2376, 2376f
 primordial, 2349, 2375, 2375f
- Germ cell tumor
 carcinoma of unknown primary and, 120e-2t, 120e-4
 extragonadal, 120e-4, 591
 ovarian, 594–595
 testicular. *See* Testicular cancer
 tumor markers in, 473t
- Germinoma, 609t, 2264–2265
- Germiston virus, 1308t
- Germline stem cells, 453t
- Germ theory of disease, 761
- Gerstmann's syndrome, 179, 2573f
- Gerstmann–Sträussler–Scheinker (GSS) disease, 444e-10, 453e-1t, 453e-4
- Gestational diabetes insipidus, 303, 2276
- Gestational diabetes mellitus, 6e-3–4, 48, 2400, 2422
- Gestational hypertension, 46
- Gestational trophoblastic disease, 597
 clinical features of, 124e-5, 597
 diagnosis of, 124e-5
 global considerations in, 597
 incidence of, 124e-5
 inflammasome activity in, 372e-8t
 paraneoplastic syndromes in, 609t
 risk factors for, 597
 treatment of, 124e-5, 597
 tumor markers in, 473t
- Gfi-1, 89e-4
- GFR. *See* Glomerular filtration rate (GFR)
- GGTP (γ -glutamyl transpeptidase), 1997, 2053, 2053t
- GH. *See* Growth hormone (GH)
- GHB. *See* γ -hydroxybutyric acid (GHB)
- GH gene mutations, 434
- GH-N gene, 2258
- Ghrelin, 415e-2
 functions of, 1912–1913, 2357–2358
 GH release and, 401e-3
 pNET secreting, 559t
- GHRH (growth hormone-releasing hormone), 401e-3, 609t, 2258, 2265